New injection targets tough blood cancers in early safety trial
NCT ID NCT07330895
First seen Jan 11, 2026 · Last updated May 06, 2026 · Updated 19 times
Summary
This early-phase study tests an injection called LV009 in 19 adults whose CD19-positive blood cancer has returned or not responded to standard treatment. The main goal is to check safety and side effects. Participants receive one infusion and are monitored for up to 24 months to see how long the effect lasts.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CD19+ RELAPSE/REFRACTORY B-ALL are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.